Patents by Inventor Yingxia Sang

Yingxia Sang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Solid form of compound
    Patent number: 11999719
    Abstract: Provided is a solid form of a compound of formula (I) or a salt thereof, or a solvate thereof, or a solvate of a salt thereof, or a mixture thereof.
    Type: Grant
    Filed: July 5, 2023
    Date of Patent: June 4, 2024
    Assignee: INXMED (NANJING) CO., LTD.
    Inventors: Zaiqi Wang, Jing Gao, Yingxia Sang
  • SOLID FORM OF COMPOUND
    Publication number: 20240051942
    Abstract: Provided is a solid form of a compound of formula (I) or a salt thereof, or a solvate thereof, or a solvate of a salt thereof, or a mixture thereof.
    Type: Application
    Filed: July 5, 2023
    Publication date: February 15, 2024
    Inventors: Zaiqi Wang, Jing Gao, Yingxia Sang
  • SOLID FORM OF COMPOUND
    Publication number: 20230278985
    Abstract: Provided is a solid form of a compound of formula (I) or a salt thereof, or a solvate thereof, or a solvate of a salt thereof, or a mixture thereof.
    Type: Application
    Filed: August 2, 2021
    Publication date: September 7, 2023
    Inventors: Zaiqi WANG, Jing GAO, Yingxia SANG
  • Compounds for inhibiting LRRK2 kinase activity
    Patent number: 11034696
    Abstract: Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: June 15, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Feng Ren, Yingxia Sang, Weiqiang Xing, Yang Zhan, Baowei Zhao
  • COMPOUNDS
    Publication number: 20210130339
    Abstract: Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: January 19, 2018
    Publication date: May 6, 2021
    Inventors: Feng REN, Yingxia SANG, Baowei ZHAO
  • Substituted fused pyrazole compounds and their use as LRRK2 inhibitors
    Patent number: 10975081
    Abstract: Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: April 13, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Xiao Ding, Yun Jin, Qian Liu, Feng Ren, Yingxia Sang, Luigi Piero Stasi, Zehong Wan, Hailong Wang, Weiqiang Xing, Yang Zhan, Baowei Zhao
  • Compounds
    Patent number: 10858367
    Abstract: Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: December 8, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Xiao Ding, Feng Ren, Yingxia Sang, Weiqiang Xing, Yang Zhan, Baowei Zhao
  • LRRK2 inhibitors for the treatment of Parkinson's disease
    Patent number: 10618901
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: April 14, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Xiao Ding, Qian Liu, Yingxia Sang, Luigi Piero Stasi, Zehong Wan, Baowei Zhao, Colin Michael Edge
  • COMPOUNDS
    Publication number: 20200079777
    Abstract: Disclosed are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: July 22, 2016
    Publication date: March 12, 2020
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Xiao DING, Yun JIN, Qian LIU, Feng REN, Yingxia SANG, Luigi Piero STASI, Zehong WAN, Hailong WANG, Weiqiang XING, Yang ZHAN, Baowei ZHAO
  • COMPOUNDS
    Publication number: 20200002323
    Abstract: Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: January 23, 2018
    Publication date: January 2, 2020
    Inventors: Haifeng CUI, Feng REN, Yingxia SANG, Xiaomin ZHANG
  • COMPOUNDS
    Publication number: 20190389850
    Abstract: The present invention provides novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: January 23, 2018
    Publication date: December 26, 2019
    Inventors: Feng REN, Yingxia SANG, Weiqiang XING, Yang ZHAN, Baowei ZHAO
  • COMPOUNDS
    Publication number: 20190359623
    Abstract: Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: January 23, 2018
    Publication date: November 28, 2019
    Inventors: Xiao DING, Feng REN, Yingxia SANG, Weiqiang XING, Yang ZHAN, Baowei ZHAO
  • COMPOUNDS FOR INHIBITING LRRK2 KINASE ACTIVITY
    Publication number: 20190359618
    Abstract: Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved.
    Type: Application
    Filed: January 23, 2018
    Publication date: November 28, 2019
    Inventors: Feng REN, Yingxia SANG, Weiqiang XING, Yang ZHAN, Baowei ZHAO
  • COMPOUNDS
    Publication number: 20180354956
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: August 2, 2018
    Publication date: December 13, 2018
    Inventors: Xiao Ding, Qian Liu, Yingxia Sang, Luigi Piero Stasi, Zehong Wan, Baowei Zhao, Colin Michael Edge
  • Compounds
    Patent number: 9815841
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: November 14, 2017
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Xiao Ding, Qian Liu, Kai Long, Yingxia Sang, Luigi Piero Stasi, Zehong Wan, Qiongfeng Xu, Colin Michael Edge
  • 2,3-dihydroimidazol[1,2-C]pyrimidin-5(1-H)-one based ipoprotein-associated phospholipase A2 (Lp-PLA) inhibitors
    Patent number: 9708330
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: July 18, 2017
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong Wan, Yingxia Sang, Qing Zhang
  • COMPOUNDS
    Publication number: 20170022204
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: January 28, 2015
    Publication date: January 26, 2017
    Inventors: Xiao DING, Qian LIU, Kai LONG, Yingxia SANG, Luigi Piero STASI, Zehong WAN, Qiongfeng XU, Colin Michael EDGE
  • COMPOUNDS
    Publication number: 20170015668
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: January 28, 2015
    Publication date: January 19, 2017
    Inventors: Xiao DING, Qian LIU, Yingxia SANG, Luigi Piero STASI, Zehong WAN, Baowei ZHAO, Colin Michael EDGE
  • 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1-H)-ONE BASED IPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS
    Publication number: 20150361082
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
    Type: Application
    Filed: January 23, 2014
    Publication date: December 17, 2015
    Inventors: Zehong WAN, Yingxia SANG, Qing ZHANG
  • Bicyclic [5,6] imidazo pyrimodone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA
    Patent number: 9051325
    Abstract: The present invention relates to bicyclic[5,6]imidazo pyrimidone compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease. In one aspect, this invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein different R groups are defined in the patent application.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: June 9, 2015
    Assignee: Glaxo Group Limited
    Inventors: Zehong Wan, Yingxia Sang, Qing Zhang